The European Medicines Agency has launched an investigation into injectable iron medicines after reports of severe hypophosphatemia leading to osteomalacia, including cases occurring after just one or two doses in patients without recognized risk factors.
Scientists have discovered that blocking the Axl receptor may offer a novel approach to promoting bone formation, potentially providing a new treatment avenue for osteoporosis, a common age-related disease affecting millions worldwide.
Multiple health sources are drawing attention to bone health management, particularly for women over 40, addressing both calcium deficiency risks and the dangers of excessive calcium supplementation that can lead to serious health complications.
